↓ Skip to main content

Dove Medical Press

Article Metrics

Exosomal microRNA-141 is upregulated in the serum of prostate cancer patients

Overview of attention for article published in OncoTargets and therapy, December 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (60th percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

twitter
2 tweeters
googleplus
1 Google+ user

Citations

dimensions_citation
62 Dimensions

Readers on

mendeley
65 Mendeley
Title
Exosomal microRNA-141 is upregulated in the serum of prostate cancer patients
Published in
OncoTargets and therapy, December 2015
DOI 10.2147/ott.s95565
Pubmed ID
Authors

Xiao-Ke Hao, Zhuo Li, Yue-Yun Ma, Juan Wang, Xian-Fei Zeng, Rui Li, Wei Kang

Abstract

Novel biomarkers for the diagnosis of prostate cancer (PCa) are urgently required. Increasing evidence suggests that exosomal microRNAs (miRNAs or miRs) in serum may be potential noninvasive biomarkers for certain diseases. The objective of the present study was to investigate and assess whether exosomal miR-141 is an effective biomarker for human PCa. In the present study, exosomes were isolated from the serum of patients with PCa, patients with benign prostate hyperplasia (BPH), and healthy volunteers. The total RNA was extracted from the exosomes and the level of miR-141 was analyzed by quantitative reverse transcription-polymerase chain reaction. The expression levels of miR-141 were compared between the whole serum and the serum exosomes of the three groups. Subsequently, the relevance of the exosomal expression of miR-141 to the clinicopathological factors in PCa was investigated. The expression of miR-141 was higher in exosomes compared with whole serum (control group, P=0.0003; BPH group, P=0.0016; PCa group, P<0.0001). The level of serum exosomal miR-141 was significantly higher in the patients with PCa compared with the patients with BPH and the healthy controls (3.85-fold, P=0.0007 and 4.06-fold, P=0.0005, respectively). In addition, the expression levels were significantly higher in metastatic PCa compared with localized PCa (P<0.0001). Receiver-operating characteristic curve revealed that the serum exosomal miR-141 yielded an area under the curve of 0.8694, with 80% sensitivity and 87.1% specificity in discriminating patients with metastatic PCa from the patients with localized PCa. Serum exosomes may serve as a more suitable material compared with the whole serum for measuring circulating miR-141 levels in patients with PCa. Exosomal miR-141 is upregulated in the serum from patients with PCa compared with patients with BPH or the healthy volunteers, and it may be a useful potential biomarker for the diagnosis of metastatic PCa.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Russia 1 2%
United States 1 2%
Unknown 63 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 21 32%
Student > Master 8 12%
Student > Bachelor 8 12%
Unspecified 7 11%
Student > Postgraduate 6 9%
Other 15 23%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 27 42%
Medicine and Dentistry 15 23%
Agricultural and Biological Sciences 11 17%
Unspecified 10 15%
Immunology and Microbiology 1 2%
Other 1 2%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 January 2016.
All research outputs
#3,006,411
of 7,312,486 outputs
Outputs from OncoTargets and therapy
#114
of 859 outputs
Outputs of similar age
#114,360
of 306,789 outputs
Outputs of similar age from OncoTargets and therapy
#17
of 208 outputs
Altmetric has tracked 7,312,486 research outputs across all sources so far. This one has received more attention than most of these and is in the 57th percentile.
So far Altmetric has tracked 859 research outputs from this source. They receive a mean Attention Score of 1.3. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 306,789 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.
We're also able to compare this research output to 208 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.